Novo Nordisk A/S (NONOF)
| Market Cap | 451.00B |
| Revenue (ttm) | 40.47B |
| Net Income (ttm) | 14.17B |
| Shares Out | n/a |
| EPS (ttm) | 3.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.52 (0.49%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 154 |
| Open | 103.50 |
| Previous Close | 105.49 |
| Day's Range | 103.50 - 103.50 |
| 52-Week Range | 94.36 - 149.55 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsNews
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints
Novo Nordisk Unusual Options Activity For November 19
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk . Looking at options history for Novo Nordisk (NYSE: NVO) we detected 45 trades. If we consider the specific...
Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment
The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest starter dose.
Novo Nordisk Launches Wegovy Weight-Loss Drug in China
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest starter dose.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated per...
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them
Eli Lilly, Novo Nordisk representatives get facetime with employers in hopes they’ll cover their drugs
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
Novo Nordisk reportedly launches Wegovy in China
Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly (LLY). Read more here.
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an ana...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Cou...
Novo Nordisk has launched obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.
Novo Nordisk Launches Wegovy in China With Prices Below US
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.
Novo Nordisk launches Wegovy in China with prices well below U.S.
Prices vary by dosage, but a one-month supply of the 0.25 mg starter dose will cost 1,400 yuan ($193.31). That’s significantly lower than the $1,349 list price in the U.S.
Kennedy's Criticism Impacts Eli Lilly and Novo Nordisk Stock Prices
Kennedy's Criticism Impacts Eli Lilly and Novo Nordisk Stock Prices
Novo Nordisk's Ozempic Launches in China for Obesity Management
Novo Nordisk's Ozempic Launches in China for Obesity Management
Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.
Novo Nordisk readies trial results for next-generation weight-loss drug
Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year
Novo Nordisk Insulin Plans Spark Angst Among Diabetes Patients
About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater access to its human insulin and lower prices, while also protesting against t...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
Novo Nordisk to phase out human insulin pens: report
Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.
Novo Nordisk says it is gradually phasing out human insulin pens globally
Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDA...